Sophie L'Helias
Known title: DirectorCIK: 0001849394
Sophie L'Helias's purchase track record
Sophie L'Helias has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/4/2026 | HLF | $14K | +6.9% | pending | — |
| 11/26/2025 | HLF | $15K | +44.4% | -7.9% | +10.4% |
| 2/21/2023 | HLF | $166K | -32.9% | -19.7% | +9.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| HLF | ▲ Buy | Open Market | 1,200 | $14K | 6/4/2026 | View on chart |
| HLF | ▲ Buy | Grant | 11,879 | $0 | 5/8/2026 | View on chart |
| HLF | ▲ Buy | Open Market | 800 | $10K | 12/1/2025 | View on chart |
| HLF | ▲ Buy | Open Market | 400 | $5K | 11/26/2025 | View on chart |
| HLF | ▲ Buy | Grant | 21,857 | $0 | 5/2/2025 | View on chart |
| HLF | ▲ Buy | Grant | 15,657 | $0 | 5/3/2024 | View on chart |
| HLF | ▲ Buy | Grant | 11,029 | $0 | 5/4/2023 | View on chart |
| HLF | ▲ Buy | Open Market | 8,500 | $166K | 2/21/2023 | View on chart |
| HLF | ▲ Buy | Grant | 5,387 | $0 | 5/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
HLF Featured in Mixed Stock Lists Amid High RSI
Recent articles from Yahoo and Benzinga discuss Herbalife in the context of long-term holdings and risk-off strategies, with one piece specifically citing reasons to avoid the stock. These mixed opinions appear while the stock trades near its 52-week high, reflecting a divergence between current price action and some analyst views. The news highlights ongoing debate over the company's value proposition among investors.
HLF Featured in Mixed Stock Lists Amid High RSI. Recent articles from Yahoo and Benzinga discuss Herbalife in the context of long-term holdings and risk-off strategies, with one piece specifically citing reasons to avoid the stock. These mixed opinions appear while the stock trades near its 52-week high, reflecting a divergence between current price action and some analyst views. The news highlights ongoing debate over the company's value proposition among investors.